Zastumotide
Vaccineexperimental
Clinical trial activity
5 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
5
Phase 3
1
Phase 4
0
Earliest trial started Sep 1, 2008 (NCT00706238)
Timeline
Indications
Studied for
Mechanism of action
- Melanoma-associated antigen 3Immunity, active
MAGEA3 immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- gsk1203486a
- gsk 2132231
- gsk2132231a
- gsk 2132231a
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00942162 | Phase 2 | Aug 1, 2009 | GlaxoSmithKline |
| NCT00849875 | Phase 2 | May 1, 2009 | GlaxoSmithKline |
| NCT00896480 | Phase 2 | May 1, 2009 | GlaxoSmithKline |
| NCT00796445 | Phase 3 | Dec 1, 2008 | GlaxoSmithKline |
| NCT00706238 | Phase 2 | Sep 1, 2008 | GlaxoSmithKline |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| GlaxoSmithKline | For profit | 5 | 5 | 2 | 2008 |
1 organizations
Page 1 / 1